drugset / Trial / NCT01018511

Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms

NCT01018511

Phase 3 Completed 1334 enrolled Astellas Pharma Europe B.V.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Clinical study to examine the efficacy, safety and tolerability of combination therapy of tamsulosin hydrochloride and solifenacin succinate compared to monotherapy of tamsulosin hydrochloride in the treatment of males with LUTS associated with BPH with a substantial storage component.

Timeline

Start
2010-01-11
Primary completion
2011-03-01
Completion
2011-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tamsulosin Other / unclassified 0.4 mg
Subject Tamsulosin Other / unclassified 6 mg
Subject Tamsulosin Other / unclassified 9 mg